This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

      

You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Thank you, doctor for taking care of your little patients. Together with your colleagues across the globe, you have helped protect over 43 million babies.*,2

Thank you for considering what really matters when choosing a 6-in-1** vaccine.

*Data on file: 174 million doses/4 = 43.5 million babies vaccinated (divided by 4 as 3+1 is the most conservative schedule available).
**Hexavalent acellular pertussis combination vaccine for prevention against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and diseases caused by Haemophilus influenzae type b
. 1

References:

  1. GlaxoSmithKline Biologicals. Infanrix hexa Summary of Product Characteristics, 2018. 
  2. GlaxoSmithKline DoF: DNG 2019N395506_00 (Number of doses distributed worldwide).

Disease & Product Overview

Burden of the diseases, risk factors and prevention

Read more

icon-book

Infanrix Hexa Prescribing Information

Combined diphtheria-tetanus-acellular pertussis, hepatitis B, enhanced inactivated polio vaccine and Haemophilus influenzae type b vaccine

Saudi Prescribing Information

Read more

All mentioned products are registered in Saudi Arabia. This page may contain promotional content. For full prescribing information or adverse events reporting, please click on the relevant button in the header or footer of this page.